These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35213029)

  • 1. Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections.
    Metz T; Kuijper EC; van Roon-Mom WMC
    Methods Mol Biol; 2022; 2434():333-341. PubMed ID: 35213029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS.
    Wahlestedt C; Khorkova O
    Cell Mol Neurobiol; 2021 Jul; 41(5):849-853. PubMed ID: 32656646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
    Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
    Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct intraventricular delivery of drugs to the rodent central nervous system.
    DeVos SL; Miller TM
    J Vis Exp; 2013 May; (75):e50326. PubMed ID: 23712122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient gene silencing in mouse brain by overhanging-duplex oligonucleotides via intraventricular route.
    Lei Mon SS; Yoshioka K; Jia C; Kunieda T; Asami Y; Yoshida-Tanaka K; Piao W; Kuwahara H; Nishina K; Nagata T; Yokota T
    FEBS Lett; 2020 May; 594(9):1413-1423. PubMed ID: 31990989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System.
    Chen Y; Mazur C; Luo Y; Sun L; Zhang M; McCampbell A; Tomassy GS
    J Vis Exp; 2019 Oct; (152):. PubMed ID: 31736489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system.
    Zeniya S; Kuwahara H; Daizo K; Watari A; Kondoh M; Yoshida-Tanaka K; Kaburagi H; Asada K; Nagata T; Nagahama M; Yagi K; Yokota T
    J Control Release; 2018 Aug; 283():126-134. PubMed ID: 29753959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense therapeutics and the treatment of CNS disease.
    Jaeger LB; Banks WA
    Front Biosci; 2004 May; 9():1720-7. PubMed ID: 14977581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor.
    Ambühl P; Gyurko R; Phillips MI
    Regul Pept; 1995 Oct; 59(2):171-82. PubMed ID: 8584752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study.
    Oberrauch S; Lu J; Cornthwaite-Duncan L; Hussein M; Li J; Rao G; Velkov T
    J Vis Exp; 2022 Mar; (181):. PubMed ID: 35435913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing gene expression in the brain via antisense methods.
    Ouagazzal AM; Tepper JM; Creese I
    Curr Protoc Neurosci; 2001 May; Chapter 5():Unit 5.4. PubMed ID: 18428503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
    Chauhan NB
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of phosphorothioate oligodeoxynucleotide antisense transport across the blood-brain barrier.
    Banks WA
    Methods Mol Biol; 2011; 789():337-42. PubMed ID: 21922419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II.
    Sakai RR; He PF; Yang XD; Ma LY; Guo YF; Reilly JJ; Moga CN; Fluharty SJ
    J Neurochem; 1994 May; 62(5):2053-6. PubMed ID: 8158154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain.
    Toonen LJA; Casaca-Carreira J; Pellisé-Tintoré M; Mei H; Temel Y; Jahanshahi A; van Roon-Mom WMC
    Nucleic Acid Ther; 2018 Apr; 28(2):63-73. PubMed ID: 29565739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein.
    Banks WA; Farr SA; Butt W; Kumar VB; Franko MW; Morley JE
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1113-21. PubMed ID: 11356936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
    Schoch KM; Miller TM
    Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System.
    Kennedy Z; Gilbert JW; Godinho BMDC
    Methods Mol Biol; 2022; 2434():345-353. PubMed ID: 35213030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.